ライフサイエンスコーパス: antitumor agent

1 ific use as an antiviral, antibacterial, and antitumor agent.

2 s for the parent compound 1, a highly potent antitumor agent.

3 ing lead for development as an antibacterial/antitumor agent.

4 ved from Brassica vegetables, is a promising antitumor agent.

5 roliferative drug, and is considered a novel antitumor agent.

6 to enter Phase 1 human clinical trials as an antitumor agent.

7 )] in the bioactivation of this DNA-damaging antitumor agent.

8 6-one (ARC-111, topovale) is a new synthetic antitumor agent.

9 xicity of doxorubicin (DOX), a commonly used antitumor agent.

10 s that is currently in clinical trials as an antitumor agent.

11 -E1 vector has potential as a broad-spectrum antitumor agent.

12 us participating as an antiangiogenic and an antitumor agent.

13 potential as a replication-competent, viral antitumor agent.

14 or (IGF-IR/AS ODN) as an effective potential antitumor agent.

15 and dihydrofolate reductase (DHFR) and as an antitumor agent.

16 metic, for refractory cancer pain, and as an antitumor agent.

17 potential of a synthetic SIFalpha as a novel antitumor agent.

18 ess to 1,3-functionalized isoquinoline-based antitumor agent.

19 e used to support further developing of this antitumor agent.

20 the formal synthesis of neolamellarin A, an antitumor agent.

21 ICOS-Fc may act as an anti-inflammatory and antitumor agent.

22 is an oral serine/threonine kinase inhibitor antitumor agent.

23 und for further preclinical evaluation as an antitumor agent.

24 to inhibit cholesterol production and act as antitumor agents.

25 benzo[a]phenoxazine derivatives as potential antitumor agents.

26 nhibitors of PKB therefore have potential as antitumor agents.

27 tic modulators with the potential for use as antitumor agents.

28 resistance by actively effluxing a number of antitumor agents.

29 assembly of the molecular framework of these antitumor agents.

30 drofolate reductase (DHFR) inhibitors and as antitumor agents.

31 ceptor (FR) alpha and beta substrates and as antitumor agents.

32 of SCF(Skp2) inhibitors as a novel class of antitumor agents.

33 of natural glycopeptides used clinically as antitumor agents.

34 deacetylase inhibitors (HDACI) are promising antitumor agents.

35 chemotherapeutic efficacy of platinum-based antitumor agents.

36 nd warrant development of these analogues as antitumor agents.

37 CDK4/cyclin D1 are attractive as prospective antitumor agents.

38 9761) is representative of a novel series of antitumor agents.

39 sunlight, environmental mutagens and certain antitumor agents.

40 selectivity characteristic of this class of antitumor agents.

41 d stability and reactivity for this class of antitumor agents.

42 rugs of the duocarmycin and CC-1065 class of antitumor agents.

43 duct biosynthesis, including antibiotics and antitumor agents.

44 drofolate reductase (DHFR) inhibitors and as antitumor agents.

45 were designed, synthesized, and evaluated as antitumor agents.

46 of previously untreated tumors to cytotoxic antitumor agents.

47 sis of the cryptophycin/arenastatin class of antitumor agents.

48 D(P)H:quinone oxidoreductase (NQO1)-directed antitumor agents.

49 nobiotic compounds, including antifungal and antitumor agents.

50 s become plausible targets for the design of antitumor agents.

51 em characteristic of the mitomycin family of antitumor agents.

52 des molecular underpinnings to develop novel antitumor agents.

53 in-polymerizing agents (MTPAs)) are powerful antitumor agents.

54 l]-l-glutamic acid (5), as TS inhibitors and antitumor agents.

55 es I and II are also targets for widely used antitumor agents.

56 S) and dihydrofolate reductase (DHFR) and as antitumor agents.

57 beneficial for design and targeting of novel antitumor agents.

58 protection and bioactivation of DNA-damaging antitumor agents.

59 been synthesized and evaluated as potential antitumor agents.

60 prevention and bioactivation of DNA-damaging antitumor agents.

61 tion with conventional chemotherapy or other antitumor agents.

62 gnificant potential to define a new class of antitumor agents.

63 nalogs were found to be potent antiviral and antitumor agents.

64 tastasis) and in the resistance mechanism to antitumor agents.

65 ic growth factors of tumors, show promise as antitumor agents.

66 lity of using proteasome inhibitors as novel antitumor agents.

67 r the development of new anti-angiogenic and antitumor agents.

68 exposure to bis-electrophiles such as common antitumor agents.

69 examination of this or related promising new antitumor agents.

70 ogenic topo II cleavable complex-stabilizing antitumor agents.

71 king compounds have emerged as important new antitumor agents.

72 of the epithelium to many cell cycle-active antitumor agents.

73 r SGLT2 inhibitors as potential antidiabetic/antitumor agents.

74 generated the most highly and broadly active antitumor agents.

75 ls could potentially be useful for targeting antitumor agents.

76 on metabolic reduction of aziridinyl quinone antitumor agents.

77 ties, as an approach for producing effective antitumor agents.

78 nd AGF154 (7)] were synthesized as potential antitumor agents.

79 vity of gold(I) analogs of platinum-acridine antitumor agents.

80 ilization in the discovery and design of new antitumor agents.

81 G function, opening new targets for platinum antitumor agents.

82 ing them good targets for the development of antitumor agents.

83 monoepoxides may represent a novel class of antitumor agents.

84 oxidizing agents, including potent cytotoxic antitumor agents.

85 m an interesting target for the synthesis of antitumor agents.

86 bons and a benozyl ring in the side chain as antitumor agents.

87 roptosis inducers, which can be optimized as antitumor agents.

88 narrow therapeutic indices of many of these antitumor agents.

89 (P)H:quinone oxidoreductase (NQO1) -directed antitumor agents.

90 he great potential of metal-NHC complexes as antitumor agents.

91 thiazole, 1a, 1b-g, are under development as antitumor agents.

92 and Ru) complexes containing NHC ligands as antitumor agents.

93 in and its analogues, are being evaluated as antitumor agents.

94 l be a superior targeted delivery system for antitumor agents.

95 ficacy and safety profile of these potential antitumor agents.

96 ld, therefore, have therapeutic potential as antitumor agents.

97 n a strategically very direct route to these antitumor agents.

98 tic modulators with the potential for use as antitumor agents.

99 This paper describes microencapsulation of antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea (BC

100 ough the reaction of adenine in DNA with the antitumor agent 1,3-bis(2-chloroethyl)-1-nitrosourea, a

101 The antitumor agent 11beta (CAS 865070-37-7), consisting of

102 the resulting limited bioavailability of the antitumor agent 2-methoxyestradiol.

103 cesses with similar kinetic efficiencies the antitumor agents 2-crotonyloxymethyl-2-cyclohexenone (CO

104 A candidate antitumor agent, 2-(4-amino-3-methylphenyl)-5-fluorobenz

105 The antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide

106 We show that the antitumor agent 4'-(9-acridinylamino)methanesulphon-m-an

107 Taxol, a successful antitumor agent, acts by promoting tubulin assembly and

108 ural product is a highly potent and specific antitumor agent against MCF-7 (breast carcinoma) cell li

109 e} was previously developed in our lab as an antitumor agent against pancreatic cancer.

110 rate that deferasirox is an orally effective antitumor agent against solid tumors.

111 ulfonamides were recently reported as potent antitumor agents against a broad spectrum of human tumor

112 lequinones (IQs) were developed as potential antitumor agents against human pancreatic cancer.

113 .e., azidothymidine) can represent promising antitumor agents, although showing high toxicity when ad

114 ,3-dihydro-1,3,4-oxadiazole (GLB) is a novel antitumor agent and belongs to glycosylated spiro-hetero

115 e results demonstrated that cGAMP is a novel antitumor agent and has potential applications in cancer

116 Dequalinium (DECA) is a potent antitumor agent and inhibitor of protein kinase C (PKC).

117 BMP4 may become an antitumor agent and open a new field of antiangiogenic t

118 the efficacy of a soluble wnt receptor as an antitumor agent and suggests that further development of

119 e may provide a target for the anthracycline antitumor agents and a candidate ferricyanide reductase

120 etics, such as PG545, have been developed as antitumor agents and are designed to suppress angiogenes

121 odomain-selective BET inhibitors that act as antitumor agents and demonstrates that these molecules h

122 ategies for the design of new RXRalpha-based antitumor agents and drug combinations.

123 an additional role in DNA damage response to antitumor agents and is associated with integrity of the

124 to the identification of a number of potent antitumor agents and the first structure-activity relati

125 he resistance of glioma cells to a number of antitumor agents and the highly invasive nature of gliom

126 al agents, including NO synthase inhibitors, antitumor agents, and antibacterials.

127 iocoraline-, azinomycin-, and bleomycin-like antitumor agents; and a rapamycin-like immunosuppressant

128 eral strategy for the total synthesis of the antitumor agent apoptolidin (1) is proposed, and the che

129 to evaluate the potential of metformin as an antitumor agent are warranted.

130 ocyanates (ITCs), as effective cytotoxic and antitumor agents are described.

131 ct the way actin- and microtubule-disrupting antitumor agents are used in tumor therapy.

132 f endoscopic tissue samples and injection of antitumor agents, are discussed.

133 has been found previously to be an effective antitumor agent attributable to deprivation of the extra

134 Doxorubicin is one of the most potent antitumor agents available; however, its clinical use is

135 oflavones have been synthesized as potential antitumor agents based on structural similarities to kno

136 The total synthesis of cytostatin, an antitumor agent belonging to the fostriecin family of na

137 documented tumor targeting properties of the antitumor agent bleomycin (BLM) were studied in cell cul

138 ve stress or treatment with the DNA-cleaving antitumor agent, bleomycin.

139 alkaloid from Xestospongia sp., is a potent antitumor agent both in vitro and in vivo.

140 Cisplatin is an important antitumor agent, but its clinical utility is often limit

141 (CHK1) are of current interest as potential antitumor agents, but the most advanced inhibitor series

142 deacetylase (HDAC) inhibitors are promising antitumor agents, but they have not been extensively exp

143 modulator of the activity of antimetabolite antitumor agents by virtue of its inhibition of nucleosi

144 of lidamycin (C-1027), a clinically relevant antitumor agent, by Streptomyces globisporus that negati

145 The total synthesis of the novel antitumor agent callipeltoside A, as well as several ana

146 ges in DNA and is the cellular target of the antitumor agent camptothecin (CPT).

147 The alpha-amino acid ester prodrugs of the antitumor agent camptothecin and a more potent, lipophil

148 Novel antitumor agents combined with nonmyeloablative HCT shou

149 PTX, an antimicrotubule agent, is a potent antitumor agent commonly used in the treatment of advanc

150 ith gemcitabine is much more effective as an antitumor agent compared with either agent alone in our

151 /or oxaliplatin is much more effective as an antitumor agent compared with either agent alone.

152 with erlotinib is much more effective as an antitumor agent compared with either agent alone.

153 A processable total synthesis of a potent antitumor agent, desoxyepothilone F (dEpoF, 21-hydroxy-1

154 ped to facilitate NQO1-directed lavendamycin antitumor agent development.

155 studies centered on the naturally occurring antitumor agent dictyostatin have recently identified se

156 first total syntheses of naturally occurring antitumor agents disorazoles A1 and B1 and the full stru

157 lts suggest that SelCID-3 represents a novel antitumor agent distinct from thalidomide and from previ

158 shown that hedamycin, a GC-rich DNA-binding antitumor agent, downregulates survivin transcription.

159 t with either the organotin compounds or the antitumor agent doxorubicin.

160 tiate the cytotoxicities of the DNA-damaging antitumor agents doxorubicin and camptothecin.

161 Although Fatostatin has been viewed as an antitumor agent due to its inhibition of SREBP and its e

162 ncer therapy; GGTase I inhibitors (GGTIs) as antitumor agents; effects of FTIs and GGTIs on cell cycl

163 -fluorobenzothiazole (5F-203) is a candidate antitumor agent empirically discovered with the aid of t

164 aving group in the 3alpha-position (like the antitumor agent EO9).

165 pine were synthesized and their potential as antitumor agents evaluated.

166 In this paper, we demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) a

167 rine derivative-1 (PBT-1) may be a potential antitumor agent for lung adenocarcinoma.

168 st cancer, and introduce Mesd as a promising antitumor agent for treating breast cancer subtypes with

169 vating the p53 pathway, promising a class of antitumor agents for cancer therapy.

170 t not in normal cells, show great promise as antitumor agents for cancer therapy.

171 VHH-based CAR T cells can thus function as antitumor agents for multiple targets in syngeneic, immu

172 y consequential for the development of viral antitumor agents for RCC and other CAR-negative tumors.

173 sible utility of trisubstituted acridines as antitumor agents for the disruption of both telomerase-d

174 rdenolides were identified as a new class of antitumor agents for the treatment of retinoblastoma.

175 l of proteasome inhibitors, a novel class of antitumor agents, for the treatment of retinoblastoma.

176 The first total synthesis of the potent antitumor agent fostriecin (CI-920) is described, confir

177 Maytansinoids are potent antitumor agents found in plants and microorganisms.

178 Ecteinascidin 743 (ET-743) is a potent antitumor agent from the Caribbean tunicate Ecteinascidi

179 vesicular stomatatis virus (VSV) as a potent antitumor agent has made a dissection of the molecular d

180 ruction of the epothilone class of promising antitumor agents has been accomplished.

181 )-crassalactone D (4), a naturally occurring antitumor agent, has been achieved by employing an oxida

182 Paclitaxel, a potent antitumor agent, has been shown to be lipopolysaccharide

183 Consequently, a large number of antitumor agents have been developed and tested for thei

184 Previously, natural product antitumor agents have been shown to interact with one of

185 Pyrrolobenzodiazepine (PBD) antitumor agents have, to date, only been observed to bi

186 rived from a class of analogous platinum(II) antitumor agents, have been synthesized.

187 iverse range of substrates including peptide antitumor agents, hormones, cyclic peptide antibiotics,

188 of DNA damage induced by many antiviral and antitumor agents; however, it remains undefined how (S)G

189 ave been proposed in the design of selective antitumor agents; however, little information is availab

190 The total synthesis of the lichen-derived antitumor agent hybocarpone (1) and related compounds is

191 as well as a variety of other drugs such as antitumor agents, immunosuppressants and antifungals.

192 a candidate for additional development as an antitumor agent in breast and other HER-2-dependent canc

193 inical proof-of-concept for BMS-754807 as an antitumor agent in combination with hormonal therapies i

194 Although it is a potent antiangiogenic and antitumor agent in many transplanted murine tumor models

195 As an antitumor agent in mice, 21 administered at its maximum-

196 ossibly other nephropathy, and also as a new antitumor agent in multiple myeloma.

197 ty and may have therapeutic potentials as an antitumor agent in the clinic.

198 he potential of DMDD as a safe and effective antitumor agent in the treatment of late-stage breast ca

199 ort the synthesis and evaluation of a potent antitumor agent in vivo for this type of breast cancer d

200 ading to the identification of 1 as a potent antitumor agent in xenograft models.

201 amilies and have been validated as potential antitumor agents in cells.

202 lore compounds that modulate this pathway as antitumor agents in GISTs.

203 and other iron chelators as investigational antitumor agents in NB therapy.

204 antiinflammatory/immunosuppressive drugs and antitumor agents in several types of lymphoma and leukem

205 ting interest in their potential efficacy as antitumor agents in the context of breast cancer.

206 eous solution at neutral pH, and were potent antitumor agents in vivo.

207 ecting endothelial cells against a number of antitumor agents including ionizing radiation.

208 low COMPARE correlations with known standard antitumor agents indicate a unique mechanism of action.

209 A new class of potential antitumor agents inspired by the enediyne antitumor anti

210 Many analogues of the antitumor agent irofulven have been readily prepared by

211 rolo[2,1-c][1,4]benzodiazepine (PBD) monomer antitumor agents is reported, establishing the molecular

212 tabolites, is an antimicrobial and potential antitumor agent isolated from Streptomyces nodosus subsp

213 (SAHA) is currently in clinical trials as an antitumor agent; it inhibits the activity of histone dea

214 Cisplatin is one of the most potent antitumor agents known, displaying clinical activity aga

215 The antitumor agent lonidamine (LND; 1-(2,4-dichlorobenzyl)-

216 miquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors.

217 osine kinases being developed as therapeutic antitumor agents may also have significant immunologic e

218 c acids derived from the amido groups of the antitumor agents mitozolomide and temozolomide have been

219 of this signaling pathway would be potential antitumor agents, particularly for SCLC.

220 he C1-16 fragment of the naturally occurring antitumor agent pectenotoxin-4.

221 and other highly potent naturally occurring antitumor agents, play a pivotal role in enabling the ad

222 n is an aureolic acid-type antimicrobial and antitumor agent produced by Streptomyces argillaceus.

223 d polyketide (PK)/nonribosomal peptide (NRP) antitumor agents, provides an ideal system to study a hy

224 The indolocarbazole antitumor agent rebeccamycin is modified by chlorine ato

225 competition, we discovered an analog of the antitumor agent rebeccamycin, a member of the increasing

226 n as the initial step in the biosynthesis of antitumor agent rebeccamycin.

227 Activation of p53 by common antitumor agents results in p53 dependent regulation of

228 The antitumor agent (-)-rhazinilam was synthesized in three

229 restricted polypharmacology in the design of antitumor agents selectively targeting the TYRO3, AXL, a

230 l synthesis of the rare but extremely potent antitumor agent shishijimicin A has been achieved via a

231 se C inhibitor D-erythro-sphinganine and the antitumor agent (+)-spisulosine, whereas the Overman rea

232 e used in the synthesis of the highly potent antitumor agents, spliceostatins, and their derivatives.

233 The synthesis of the potent antitumor agent (+/-)-streptonigrin has been achieved in

234 trast, benzoquinone-based aziridinyl quinone antitumor agents such as AZQ, DZQ, and the new benzoquin

235 involved in the transport of platinum-based antitumor agents such as cisplatin (CDDP); however, the

236 linking two strands of DNA and are formed by antitumor agents such as cisplatin and nitrogen mustards

237 When cell growth is inhibited by antitumor agents such as doxorubicin, capsaicin, and ant

238 Commonly used antitumor agents, such as DNA topoisomerase I/II poisons

239 of the cytotoxicity of gamma-radiolysis and antitumor agents, such as the enediynes.

240 f dual major-groove alkylating/intercalating antitumor agents, such as the pluramycins.

241 The activity of the novel antitumor agent tasquinimod (TASQ) with S100A9 as a mole

242 ch for the construction of the potent marine antitumor agents (+)-tedanolide (1) and (+)-13-deoxyteda

243 rose, an unusual sugar found attached to the antitumor agent tetrocarcin A or the antibiotic kijanimi

244 and the discovery of a number of more potent antitumor agents than their parent naturally occurring m

245 AF was found to be a potent and effective antitumor agent that caused tumor regression in the MDA-

246 We report here the development of an antitumor agent that downregulates Id1 effectively in tu

247 ults suggest that Metastatin is an effective antitumor agent that exhibits antiangiogenic activity.

248 struction of novobiocin, a clinically useful antitumor agent that has been shown to inhibit both type

249 Taxol is a commonly used antitumor agent that hyperstabilizes microtubules and pr

250 l curcumin-related compound EF24 is a potent antitumor agent that induces caspase-mediated apoptosis

251 Vinblastine is an important antitumor agent that induces G(2)-M arrest and subsequen

252 ONC201/TIC10 is a first-in-class antitumor agent that induces TRAIL pathway-mediated cell

253 Our findings indicate that EF24 is a potent antitumor agent that inhibits tumor growth and metastasi

254 Tirapazamine (1) is a promising antitumor agent that selectively causes DNA damage in hy

255 Enzastaurin - a novel oral antitumor agent that selectively inhibits protein kinase

256 Compound 3b has emerged as a promising antitumor agent that shows excellent in vivo efficacy an

257 Discodermolide is a potentially important antitumor agent that stabilizes microtubules and blocks

258 Furthermore, aurothiomalate is an effective antitumor agent that targets the tumor-initiating stem c

259 mpounds triostin and thiocoraline are potent antitumor agents that act as DNA bisintercalators.

260 Histone deacetylase (HDAC) inhibitors are antitumor agents that also have antiinflammatory propert

261 The development of novel antitumor agents that have high efficacy in suppressing

262 ed that thiosemicarbazones (TSCs) are potent antitumor agents that inhibit Topo-II.

263 ne ansamycins (BQAs) are a valuable class of antitumor agents that serve as inhibitors of heat shock

264 so as novel chemical matter that may lead to antitumor agents that specifically interfere with cancer

265 em for dissecting the mechanism of action of antitumor agents that target type II DNA topoisomerases.

266 These results provide a lead for antitumor agents that would selectively destroy cells in

267 Ionizing radiation and the antitumor agents, the bleomycins (BLMs) and enediynes, s

268 The antitumor agent thiocoraline is a nonribosomally biosynt

269 esulting from one-electron activation of the antitumor agent tirapazamine by the enzymes xanthine/xan

270 is among the most highly and broadly active antitumor agents to have been evaluated in our laborator

271 is among the most highly and broadly active antitumor agents to have been evaluated in our laborator

272 rlotinib with OSU-03012, a celecoxib-derived antitumor agent, to overcome EGFR inhibitor resistance i

273 d total synthesis of the naturally occurring antitumor agents trioxacarcins is described, along with

274 A disodium phosphonooxymethyl prodrug of the antitumor agent triptolide was prepared from the natural

275 To further develop AHNP as an antitumor agent useful for preclinical trials and as a r

276 Traditional approaches to evaluating antitumor agents using human tumor xenograft models have

277 ynthesis of novel unsymmetrical bifunctional antitumor agents was accomplished by linking an imidazoa

278 ine were synthesized, and their potential as antitumor agents were examined.

279 xane N-pyridyl derivatives as iron-depleting antitumor agents were prepared.

280 zed abasic sites that are produced by potent antitumor agents were shown to inactivate DNA polymerase

281 ibitor entinostat is emerging as a promising antitumor agent when added to the standard-of-care treat

282 etic novel alkylphospholipid, a new class of antitumor agents which targets cell membranes and inhibi

283 developed OSU-2S, a novel PKCdelta-targeted antitumor agent, which is devoid of S1P1 receptor activi

284 d here represents a novel class of potential antitumor agents, which potently and selectively inhibit

285 Bleomycin is an antitumor agent whose cytotoxicity is dependent on its a

286 yl)benzamide (CB30865) is a quinazolin-4-one antitumor agent whose high growth-inhibitory activity (W

287 brief summary of the development of FTIs as antitumor agents will be given.

288 C-1027 is a potent antitumor agent with a previously undescribed molecular

289 trapping agent results in a markedly active antitumor agent with low toxicity.

290 conclusion, TF-011-MMAE is a promising novel antitumor agent with potent activity in xenograft models

291 kylphospholipids (ALKs) are a novel class of antitumor agents with an unknown mechanism of action.

292 ndicate that dEpoB and dEpoF are efficacious antitumor agents with both a broad chemotherapeutic spec

293 d as part of our program to provide targeted antitumor agents with folate receptor (FR) cellular upta

294 Therapeutic strategies coupling antitumor agents with inhibition of immunosuppressive ce

295 The duocarmycins are potent antitumor agents with potential for use in the developme

296 3-desoxyepothilone B (dEpoB), a new class of antitumor agents with promising in vivo preclinical prop

297 Laulimalide represents a new class of antitumor agents with significant clinical potential.

298 Unsymmetrical bifunctional antitumor agent WMC79 was further optimized to generate

299 gitoxosylmithramycin SK could be a promising antitumor agent worthy of further investigation.

300 f anti-inflammatory ([ZrO](2+)[BMP](2-)) and antitumor agents ([ZrO](2+)[FdUMP](2-)) with an up to 80